Advances of second-line therapy for small-cell lung cancer

doi:10.3760/cma.j.issn.1673-422X.2017.04.013

Abstract

Abstract: Small cell lung cancer (SCLC) is a highly malignant tumor, which is very sensitive to firstline chemotherapy, but easy to recurrence and metastasis early. So it always has poor prognosis. Secondline therapy for SCLC develops slowly. Topotecan is the only drug approved by US Food and Drug Administration as a secondline chemoradiotherapy. Numerous studies on molecular targeted therapy and immunotherapy are being carried out, but most of them have no or little benefit. Rovalpituzumab tesirine (RovaT) targeted antibodydrug conjugate (ADC) which is published at the 2016 American Society of Clinical Oncology Annual Meeting shows a good antitumor activity, which seems to bring a new dawn of molecular targeted therapy.

Key words: Lung neoplasms, Carcinoma, small cell, Retreatment, Drug therapy

Yang Hongjuan, Xie Conghua.. Advances of second-line therapy for small-cell lung cancer[J]. Journal of International Oncology, 2017, 44(4): 290-293.

References

［1］ Spigel DR, Socinski MA. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches［J］. J Thorac Oncol, 2013, 8(5): 587-598. DOI: 10.1097/JTO.0b013e318286cf88. ［2］ Parsons A, Daley A, Begh R, et al. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis［J］. BMJ, 2010, 340: b5569. DOI: 10.1136/bmj.b5569. ［3］ Hartwell D, Jones J, Loveman E, et al. Topotecan for relapsed small cell lung cancer: a systematic review and economic evaluation［J］. Cancer Treat Rev, 2011, 37(3): 242-249. DOI: 10.1016/j.ctrv.2010.07.005. ［4］ Heist RS, Fain J, Chinnasami B, et al. PhaseⅠ/Ⅱ study of AT-101 with topotecan in relapsed and refractory small cell lung cancer［J］. J Thorac Oncol, 2010, 5(10): 1637-1643. DOI: 10.1097/JTO.0b013e3181e8f4dc. ［5］ Spigel DR, Waterhouse DM, Lane S, et al. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an openlabel multicenter single-arm phase Ⅱ study［J］. Clin Lung Cancer, 2013, 14(4): 356-363. DOI: 10.1016/j.cllc.2012.12.003. ［6］ Ettinger DS, Jotte R, Lorigan P, et al. Phase Ⅱ study of amrubicin as secondline therapy in patients with platinumrefractory smallcell lung cancer［J］. J Clin Oncol, 2010, 28(15): 2598-2603. DOI: 10.1200/JCO.2009.26.7682. ［7］ von Pawel J, Jotte R, Spigel DR, et al. Randomized phase Ⅲ trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer［J］. J Clin Oncol, 2014, 32(35): 4012-4019. DOI: 10.1200/JCO.2013.54.5392. ［8］ Sevinc A, Kalender ME, Altinbas M, et al. Irinotecan as a secondline monotherapy for small cell lung cancer［J］. Asian Pac J Cancer Prev, 2011, 12(4): 1055-1059. ［9］赵明利, 毕清, 任宏轩, 等. 伊立替康与拓扑替康二线治疗43例小细胞肺癌的临床观察［J］. 中国癌症杂志, 2011, 21(2): 156158. DOI: 10.3969/j.issn.1007-3969.2011.02.016. ［10］ Jeong J, Cho BC, Sohn JH, et al. Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase Ⅱ trial［J］. Lung Cancer, 2010, 70(1): 77-81. DOI: 10.1016/j.lungcan.2010.01.006. ［11］ Kim GM, Kim YS, Ae Kang Y, et al. Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients［J］. J Thorac Oncol, 2012, 7(4): 731-736. DOI: 10.1097/JTO.0b013e31824b23cb. ［12］ Goto K, Ohe Y, Shibata T, et al. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as secondline treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, openlabel, randomised phase 3 trial［J］. Lancet Oncol, 2016, 17(8): 1147-1157. DOI: 10.1016/S1470-2045(16)30104-8. ［13］ Jalal S, Bedano P, Einhorn L, et al. Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group［J］. J Thorac Oncol, 2010, 5(12): 2008-2011. DOI: 10.1097/JTO.0b013e3181f77b6e. ［14］ Mountzios G, Emmanouilidis C, Vardakis N, et al. Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: a phase Ⅱ multicenter study of the Hellenic Oncology Research Group［J］. Lung Cancer, 2012, 77(1): 146-150. DOI: 10.1016/j.lungcan.2012.02.002. ［15］ Waterhouse DM, Morgan SK, Spigel DR, et al. Phase Ⅱ study of oral topotecan plus bevacizumab (topo-bev) for second-line treatment of small cell lung cancer (SCLC)［J］. J Clin Oncol, 2010, 28 Suppl 15s: abstr 7055. DOI: 10.1200/jco.2010.28.15_suppl.7055. ［16］ Ready NE, Pang HH, Gu L, et al. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: a randomized, doubleblind, placebo-controlled phase Ⅱ study-CALGB 30504 (Alliance)［J］. J Clin Oncol, 2015, 33(15): 1660-1665. DOI: 10.1200/JCO.2014.57.3105. ［17］ Han JY, Kim HY, Lim KY, et al. A phase Ⅱ study of sunitinib in patients with relapsed or refractory small cell lung cancer［J］. Lung Cancer, 2013, 79(2): 137-142. DOI: 10.1016/j.lungcan.2012.09.019. ［18］ Rudin CM, Hann CL, Garon EB, et al. Phase Ⅱ study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer［J］. Clin Cancer Res, 2012, 18(11): 3163-3169. DOI: 10.1158/1078-0432.CCR-11-3090. ［19］ Wainberg ZA, Rafii S, Ramanathan K, et al. Safety and antitumor activity of the PARP inhibitor BMN673 in a phase Ⅰ trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCAmutation carrier cancer patients［J］. J Clin Oncol, 2014, 32 Suppl 5: abstr 7522. ［20］ Saunders LR, Bankovich AJ, Anderson WC, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo［J］. Sci Transl Med, 2015, 7(302): 302ra136. DOI: 10.1126/scitranslmed.aac9459. ［21］ Rudin CM, Pietanza MC, Bauer TM, et al. Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)targeted antibodydrug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC)［J］. J Clin Oncol, 2016, 34 Suppl: abstr LBA8505. ［22］ Ott PA, Fernandez MEE, Hiret S, et al. Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): preliminary safety and efficacy results from KEYNOTE028［J］. J Clin Oncol, 2015, 33 Suppl: abstract 7502. ［23］ Antonia SJ, LópezMartin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, openlabel, phase 1/2 trial［J］. Lancet Oncol, 2016, 17(7): 883-895. DOI: 10.1016/S1470-2045(16)30098-5.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Yue Hongyun, Zhang Baihong. Differentiation therapies in human cancers [J]. Journal of International Oncology, 2024, 51(2): 109-113.
[4]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[5]	He Jiahui, Hu Qinyong. Comparative analysis of lung cancer incidence and mortality trends and risk factors in China and the United States based on GBD data [J]. Journal of International Oncology, 2024, 51(1): 29-36.
[6]	Li Chenxi, Zhao Hongwei. Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery [J]. Journal of International Oncology, 2023, 50(6): 342-347.
[7]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[8]	Zuo Xiaoping, Liu Xiaochuan, Wu Xiqiang, Li Zhou, Xia Tian, Liu Guofeng. Risk factors and prediction model construction of arrhythmia in elderly patients with early lung cancer after thoracoscopic pulmonary resection [J]. Journal of International Oncology, 2023, 50(12): 711-716.
[9]	Chen Yu, Xu Hua, Liu Hai, Chen Shixin. Construction of pathological classification prediction model for malignant pulmonary pure ground-glass nodule patients based on CT imaging [J]. Journal of International Oncology, 2023, 50(11): 655-660.
[10]	Chen Yi, Han Liang, Cai Li. Multivariate analysis of chemotherapy induced oral mucositis in patients with head and neck tumors [J]. Journal of International Oncology, 2022, 49(9): 521-525.
[11]	Yang Sha, Yang Xiaohua, Wang Suhua, Xue Xiaoyan, Xu Jun. Analysis of risk factors for deep vein thrombosis of lower extremity after thoracoscopic surgery for elderly lung cancer and establishment and validation of prediction model [J]. Journal of International Oncology, 2022, 49(9): 532-536.
[12]	Chen Huangjing, Zhu Pengfei, Zhang Qing, Chen Guifang, Yang Chunlin, He Ying. Comparative study on the clinical value of contrast-enhanced ultrasound- and CT-guided percutaneous puncture biopsy in peripheral lung masses [J]. Journal of International Oncology, 2022, 49(8): 459-463.
[13]	Chu Xuelei, Mao Yun, Xue Peng, Li Linlu, Chen Meichi, Yuan Chunsheng, Qin Xiaoyan, Zhu Shijie. Effects of chemotherapy dose intensity on short-term efficacy in patients with advanced colon cancer： a study based on real-world data [J]. Journal of International Oncology, 2022, 49(7): 408-415.
[14]	Cai Gangxiang, Li Jing, Xu Bin. Advances in neoadjuvant immunotherapy for lung cancer [J]. Journal of International Oncology, 2022, 49(6): 366-370.
[15]	Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali. Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer [J]. Journal of International Oncology, 2022, 49(5): 276-281.